Abstract | BACKGROUND: METHODS AND RESULTS: After developing CFVs, dogs received a vehicle or OPC-29030 intravenously. Plasma and intraplatelet 12-HETE levels increased after CFVs. OPC-29030 but not vehicle reduced CFVs, which was associated with decreases in plasma and intraplatelet 12-HETE levels. Cessation of OPC-29030 restored CFVs in association with increases in plasma and intraplatelet 12-HETE levels. ADP and U46619 induced ex vivo platelet 12-HETE production and aggregation. After OPC-29030 administration, the ADP- and U46619-induced increases in ex vivo platelet 12-HETE production and aggregation were inhibited significantly. Platelet aggregation was linearly correlated with platelet 12-HETE production. OPC-29030 suppressed activation of human platelet glycoprotein IIb/IIIa. CONCLUSIONS:
|
Authors | A Katoh, H Ikeda, T Murohara, N Haramaki, H Ito, T Imaizumi |
Journal | Circulation
(Circulation)
1998 Dec 22-29
Vol. 98
Issue 25
Pg. 2891-8
ISSN: 0009-7322 [Print] United States |
PMID | 9860792
(Publication Type: Journal Article)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Thromboxane A2
- 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
|
Topics |
- 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
(antagonists & inhibitors, metabolism, physiology)
- Animals
- Aorta
(drug effects, physiology)
- Blood Platelets
(metabolism)
- Blood Pressure
(drug effects)
- Coronary Thrombosis
(etiology, metabolism)
- Dogs
- Heart Rate
(drug effects)
- Platelet Aggregation Inhibitors
(pharmacology)
- Platelet Glycoprotein GPIIb-IIIa Complex
(metabolism)
- Thromboxane A2
(metabolism)
|